Including the recent investment projects announcement, GHIT has invested approximately 14.1 billion yen ($124 million) in 77 global product development partnerships.
The new grant from the GHIT Fund will further development of processes to move the vaccine from the experimental stage to human trials and, ultimately, a clinical treatment.